These results show 2a with a 4-substituted resorcinol is a promising novel candidate for the treatment of skin pigment disorders, and that tyrosinase inhibition can be significantly increased with the 4-substituted resorcinol entity alone without the α,β-unsaturated carbonyl motif. The gene discussed is TYR; the disease is skin pigmentation disorder.